Skip to main content
SpringerLink
Log in

Thymosin α1: Chemistry, Mechanism of Action and Clinical Applications

  • Chapter
Combination Therapies 2

Abstract

Thymosin α1, is a 28 amino acid, 3108 molecular weight acidic peptide isolated from thymosin fraction 5 (1). Its amino acid sequence is homologous in murine, bovine and human species (2) and a chemically synthesized version (3) has shown activity similar to the native peptide in modulating T-cell maturation (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Low T.L.K., et al. I. I.olation, characterization, and biological activities of thymosin alpha-1 and polypeptide bi from calf thymus. J. Biol. Chem. 1979, 254: 981–86.

    PubMed  CAS  Google Scholar 

  2. Low, T.L.K., et al., In: “The Year in Hematology,” (1978) 281–319.

    Google Scholar 

  3. Wang, S.-S., Synthesis of Thymosin al. U.S. Patent No. 4, 148, 788. 1979.

    Google Scholar 

  4. Schulof R.S., et al. Thymic Factors, In Biological Response Modifiers and Cancer Therapy, 1988, Marcel Dekker, Inc.

    Google Scholar 

  5. Serrate S.A., et al. Modulation of human natural killer cell cytotoxic activity, lymphokine production and interleukin 2 receptor expression by thymic hormones. J. Immunol. 1987, 139: 2338–2343.

    PubMed  CAS  Google Scholar 

  6. Baxevanis C.N., et al. Enhancement of human T lymphocyte function by prothymosin alpha: increased production of interleukin-2 and expression of interleukin-2 receptors in normal human peripheral blood T lymphocytes. Immunopharmac. and Immunotoxic. 1990, 12 (4): 595–617.

    Article  CAS  Google Scholar 

  7. Hu S.-K., et al. Thymosin enhances the production of IL-la by human peripheral blood monocytes. Lymphokine Res. 1989, 8 (3): 203–214.

    PubMed  CAS  Google Scholar 

  8. Leichtling K.D., et al. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int. J. Immunopharmac. 1990, 12: 19–29.

    Article  CAS  Google Scholar 

  9. Sztein M.B., et al. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl. Acad. Sci. U.S.A. 1986, 83: 6107–6111.

    Article  PubMed  CAS  Google Scholar 

  10. Sztein, M.B., et al. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int. J. Immunopharmac. 1989, 11 (7): 789–800.

    Article  CAS  Google Scholar 

  11. Favalli C., et al. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol. Immunother. 1985, 20: 189–192.

    Article  CAS  Google Scholar 

  12. Baxevanis C.N., et al. Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin enhances while thymosin B4 suppresses the human autologous and allogeneic mixed lymphocyte reaction. Immunopharm. 1987, 13: 133–141.

    Article  CAS  Google Scholar 

  13. Frasca, D., et al., Reconstitution of T cell functions in aging mice by Thymosin al. Immunopharmacology (1986) 11: 155–163.

    Article  PubMed  CAS  Google Scholar 

  14. Bach, J.F., et al., Appearance of T-cell markers in bone marrow rosette forming cells after incubation with thymosin, a thymic hormones. Proc. Natl. Acad. Sci., 68: 2735–2738.

    Google Scholar 

  15. Huang, K.-Y., et al., Thymosin treatment modulates production of Interferon. J. Interferon Rsch. (1981) 1: 3: 411–420.

    Article  CAS  Google Scholar 

  16. Hsai, J., et al., Peripheral blood mononuclear cell Interleukin-2 and Interferon-a production, cytoxicity, and antigen-stimulated blastogenesis during experimental rhinovirus infection. J. of Infectious Diseases. (1990) 162: 591–597.

    Article  Google Scholar 

  17. Ohta, Y., et al., Thymosin al enhances haemopoietic colony formation by stimulating the production of Interleukin 3 in nu/nu mice. Int. J. Immunopharmac. (1986) 8: 7: 773–779.

    Article  CAS  Google Scholar 

  18. Mastino, A., et al., Thymosin al potentiates interleukin 2 induced cytotoxic activity in mice. Cell. Immunol., (1991) 133: 196–205.

    Article  PubMed  CAS  Google Scholar 

  19. Mastino, et al., Combination therapy with thymosin alpha 1 potentiates the antitumor activity of Interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int. J. Cancer (1992) 50: 493–499.

    Article  PubMed  CAS  Google Scholar 

  20. Garaci et al., Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol. Immunother. (1990) 32: 154–160.

    Article  CAS  Google Scholar 

  21. Ershler, et al., Effects of thymosin alpha 1 on specific antibody response and susceptibility to infection in young and aged mice. Int. J. Immunopharm. (1985) 7: 465–471.

    Article  CAS  Google Scholar 

  22. Shiau, et al., The effects of thymosin on experimental herpes simplex virus infections. J. Formoson Med. Assoc. (1988) 87: 34–71.

    CAS  Google Scholar 

  23. Effros, et al., The effect of thymosin alpha 1 on immunity to influenza in aged mice. In Aging: Immunology and Infectious Disease. (1988) 1: 31–40.

    Google Scholar 

  24. Ishitsuka, et al., Protective activity of thymosin against opportunistic infections in animal models. Immunol. Immunotherapy. (1983) 144–150.

    Google Scholar 

  25. Bistoni, et al., Increase of mouse resistance to Candida Albicar infection by thymosin alpha 1. Infect. Immun. (1982) 36: 609–614.

    PubMed  CAS  Google Scholar 

  26. Salvin, S.B., In vivo effects of Thymosin on cellular immunity. Clin. Immun. Newsletter. (1984) 5: 9: 129–135.

    Article  Google Scholar 

  27. Korba, B.E., et al., Treatment of Chronic Woodchuck Hepatitis Virus Infection with Thymosin alpha 1. Hepatology (1990) 12: 880

    Google Scholar 

  28. Basides, A.M., et al., Thymosin Alpha-1: First clinical trial and comparison with thymosin fraction 5. Current Contents in Human Immunol. and Cancer Immunomodulation. (1982) 567–574.

    Google Scholar 

  29. Dillman, R.O., et al., Phase I trials of thymosin fraction 5 and Thymosin al. J. of Biolog. Resp. Mod. (1982) 1: 35–41.

    Google Scholar 

  30. McConnell, L.T., et al., Augmentation of influenza antibody levels and reduction in attach rates in elderly subjects by thymosin alpha 1 (TA1). The Gerontologist (1989) 29: 188A.

    Google Scholar 

  31. Gravenstein, S., et al., Augmentation of influenza antibody response in elderly men by Thymosin alpha one, A double-blind placebo-controlled clinical study. JAGS (1989) 37: 1–8.

    CAS  Google Scholar 

  32. McConnell, L.T., Influenza vaccine and adjuvant thymosin alpha-1: A double-blind placebo-controlled trial. (Unpublished report).

    Google Scholar 

  33. Shen, S.Y., et al., Age-Dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients. In: Biomedical advances in aging. (1990) 523–530.

    Chapter  Google Scholar 

  34. Shen, S.Y., et al., Increases in specific antibody responses to influenza vaccine responses with adjuvant thymosin alpha 1 in chronic hemodialysis patients. (Unpublished report).

    Google Scholar 

  35. Shen, S., et al., Effects of thymosin alpha 1 (TAl) on peripheral T-cell and heptavax-B vaccination (V) in previously non-responsive hemodialysis (HD patients (Pts). Hepatology (1987) 7: 1120.

    Google Scholar 

  36. Dillman, R.O., et al., In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin al. J. of Biolog. Resp. Mod. (1983) 2: 139–149.

    CAS  Google Scholar 

  37. Wolfe, G.T. Prospective randomized trial of thymosin alpha (Tal) immune reconstitution in patients with advanced head and neck squamous carcinoma (HNSC): 5 year results. In: Proceedings of the American Association for Cancer Research (1989) 30: 261.

    Google Scholar 

  38. Schulof, R.S., et al., A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-al in patients with lung cancer. J. Biolog. Resp. Mod. (1985) 4: 147–158.

    CAS  Google Scholar 

  39. Mutchnick, M.G., et al., Thymosin treatment of chronic hepatitis B a placebo-controlled pilot trial. Hepatology (1991) 14: 3: 409–415.

    Article  PubMed  CAS  Google Scholar 

  40. Mutchnick, M., et al., Sustained response to thymosin therapy in patients with chronic active hepatitis B ( CAHB ). Second International Symposium on Combination Therapies. (1992) 36.

    Google Scholar 

  41. Schulof, R.S., et al., Phase I/II Trial of thymosin fraction 5 and thymosin alpha one in HTLV-111 Seropositive Subjects. J. Biolog. Resp. Mod. (1986) 3: 429–443.

    Google Scholar 

  42. Garaci, E., et al., Combined therapy with zidovudine -thymosin alpha 1- alpha interferon in the treatment of HIV-infected patients. Second International Symposium on Combination Therapies. (1992) 33.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, The George Washington University School of Medicine, Washington, D.C., 20037, USA

    Allan L. Goldstein

Authors
  1. Allan L. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Rome “Tor Vergata”, Rome, Italy

    Enrico Garaci

  2. The Institute for Advanced Studies in Immunology and Aging, Washington, D.C., USA

    Allan L. Goldstein

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Goldstein, A.L. (1993). Thymosin α1: Chemistry, Mechanism of Action and Clinical Applications. In: Garaci, E., Goldstein, A.L. (eds) Combination Therapies 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2964-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2964-4_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6289-0

  • Online ISBN: 978-1-4615-2964-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation